Percutaneous arteriovenous fistula creation.

Area of Science:

• Vascular Surgery
• Nephrology
• Medical Devices

Background:

• Percutaneous arteriovenous fistula creation for hemodialysis is a novel approach.
• The Ellisys and WavelinQ systems represent the first FDA-approved devices for this purpose, introduced in 2018.

Purpose of the Study:

• To review the technical aspects, patient selection, and outcomes of the Ellisys and WavelinQ percutaneous arteriovenous fistula systems.
• To compare the two leading percutaneous arteriovenous fistula devices for hemodialysis.

Main Methods:

• Review of technical design, energy sources, imaging needs, and procedural techniques for Ellisys and WavelinQ.
• Analysis of patient selection criteria, postoperative evaluation, and intervention strategies.
• Examination of outcomes, complications, and cannulation issues associated with these devices.

Main Results:

• Both Ellisys and WavelinQ utilize key vascular elements in the cubital fossa, differing in technical design and procedural requirements.
• Early and longer-term data suggest potential benefits and improved outcomes in select patient populations.
• Successful creation of arteriovenous fistulas is dependent on specific patient anatomy and procedural technique.

Conclusions:

• Percutaneous arteriovenous fistula creation using Ellisys and WavelinQ offers a new minimally invasive option for hemodialysis access.
• Careful patient selection and understanding of device-specific techniques are crucial for optimal outcomes.
• Further research and long-term follow-up are necessary to fully establish the role of these devices in hemodialysis patient care.